Japan's AnGes begins phase 2/3 clinical trial of DNA-based COVID-19 vaccine

Japanese biotech company AnGes Inc said on Tuesday it had initiated a phase 2/3 clinical trial of its DNA-based COVID-19 vaccine candidate.

The study is taking place at eight facilities in eastern and western Japan involving 500 test subjects, the company said in a statement.

Also Read: Odd News Roundup: Giant Japanese robot spurs hopes for tourism after virus hit; Monolith mystery deepens as Utah desert object vanishes and more